Dr. Jeffrey M. Dayno is the President and CEO of Harmony Biosciences Holdings, Inc., having taken the role permanently in April 2023 after serving as Interim CEO since January 2023. With a strong medical background, Dr. Dayno holds an M.D....
Dr. Jeffrey M. Dayno is the President and CEO of Harmony Biosciences Holdings, Inc., having taken the role permanently in April 2023 after serving as Interim CEO since January 2023. With a strong medical background, Dr. Dayno holds an M.D. from Temple University School of Medicine and has more than 20 years of experience in the pharmaceutical industry. His career includes key roles at notable companies such as Merck & Co., Inc., where he contributed to global medical affairs, and ViroPharma, Inc., prior to its acquisition by Shire Pharmaceuticals. Before his leadership at Harmony, he was the Chief Medical Officer at Zyla Life Sciences. Beyond his corporate roles, Dr. Dayno is also known for his involvement with the Philadelphia Stroke Council, where he served as Chairman, highlighting his commitment to healthcare advancements. In his current role, he aims to enhance Harmony's pipeline while driving clinical development programs and strengthening the company's financial health. His strategic focus has already shown results, with significant revenue achievements; for instance, in 2023, the company reported net product revenues of $582 million. Dr. Dayno’s approach to leadership is practical and results-oriented, aligning medical goals with business objectives, thus positioning Harmony for future growth.